BAT Sells 3.5% Stake in ITC for $2.1 Billion

BAT by 2FIRSTS.ai
Mar.14.2024
BAT Sells 3.5% Stake in ITC for $2.1 Billion
British American Tobacco (BAT) sells 3.5% stake in India's ITC Ltd for $2.1 billion, retaining 25.5% ownership.

According to a report from the Indian media outlet Theweek, British American Tobacco (BAT) sold a 3.5% stake in Indian Tobacco Company (ITC Ltd) through a public market transaction on March 13, with the total transaction amount reaching 174.85 billion rupees ($2.1 billion USD).

 

Despite completing this major transaction, BAT remains an important shareholder of ITC, holding a 25.5% stake in the company. Other shareholders of ITC include the Singapore government, Singapore Monetary Authority, Lockheed Martin Corporation, Goldman Sachs (Singapore), Copthall Mauritius Investments, BofA Securities Europe SA, Societe Generale, Morgan Stanley Asia Singapore Limited, and Ghisallo Master Fund LP.

 

BAT has sold over 436.8 million equity shares through its subsidiary India Tobacco Manufacturers (India) Ltd, in 48 transactions, equivalent to a 3.5% stake in ITC. The average selling price for these shares was 400.25 Indian rupees per share, with a total transaction value of 174.85 billion Indian rupees.

 

Over 30 institutions purchased shares in this sale, including ICICI Prudential Mutual Fund, Motilal Oswal MF, Nippon India MF, SBI MF, Max Life Insurance Company, IMF, Capital Group, Kuwait Investment Authority, The People's Bank of China, and International Bank for Reconstruction and Development.

 

It is reported that BAT plans to use the net proceeds from this bulk transaction to buy back its own shares by December 2025, starting as early as 2024, with a total amount of up to 700 million pounds. In addition, BAT will continue to use operating cash flow to fund its transformation and further reduce debt.

 

The initial investment by BAT in ITC can be traced back to the early 20th century, with both companies maintaining a mutually beneficial relationship for an extended period of time.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Largest Vape Retailer Shosha Faces Advertising Probe Over Offshore Website and Local Fulfilment
New Zealand's Ministry of Health is reviewing its previous assessment of Shosha Global, an international website associated with vape retailer Shosha, after researchers found that the site displayed vaping products while fulfilling orders to New Zealand addresses. Radio New Zealand reported on November 13 that test purchases arrived within three days and shipping documents showed dispatch from Auckland. The researchers also found a store-stock tool listing only New Zealand locations and social media posts carrying local warning labels and cultural references. Shosha, which operates more than 125 stores in New Zealand, says Shosha Global serves overseas customers through an international partnership established in July 2025. No final regulatory finding against the website has been announced.
Regulations
Nov.17
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23